Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NANODX via ACUITY STRATEGIC PARTNERS LLC
2026 · second_quarter · Q2
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Source: Senate LDA
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2026 · first_quarter · Q1
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · fourth_quarter · Q4
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · third_quarter · Q3
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · second_quarter · Q2
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2025 · first_quarter · Q1
Medical device development, reimbursement for point of care services
Medical device development, reimbursement for point of care services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · fourth_quarter · Q4
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · third_quarter · Q3
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · second_quarter · Q2
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2024 · first_quarter · Q1
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · fourth_quarter · Q4
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NANODX via ACUITY STRATEGIC PARTNERS LLC
2023 · third_quarter · Q3
Medicare and Medicaid rare diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · second_quarter · Q2
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2023 · first_quarter · Q1
Medicare and Medicaid reimbursement
Medicare and Medicaid reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · fourth_quarter · Q4
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · third_quarter · Q3
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · second_quarter · Q2
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · 1A
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PARATEK PHARMACEUTICALS via ACUITY STRATEGIC PARTNERS LLC
2022 · first_quarter · RR
Rare Disease research and Medicaid/Medicare reimbursement
Rare Disease research and Medicaid/Medicare reimbursement